<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550534</url>
  </required_header>
  <id_info>
    <org_study_id>198/UN2.F1/ETIK/2015</org_study_id>
    <nct_id>NCT03550534</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia</brief_title>
  <official_title>The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia: A Double Blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patient with stage 3 or 4 chronic kidney disease (CKD) usually has normal level
      of serum phosphate, due to increased serum fibroblast growth factor-23 (FGF23) level that
      resulted in increased phosphate urine excretion. On the other hand, serum FGF23 elevation was
      related to CKD progression, vascular calcification, cardiomegaly, and mortality. This double
      blind, randomized controlled trial study was conducted to evaluate effectiveness and safety
      of calcium carbonate administration in stage 3 or 4 CKD patients with normophosphatemia.

      Hypothesis: Calcium carbonate administration is effective and safe in chronic kidney disease
      (CKD) with normophosphatemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is the most cause of mortality of chronic kidney disease (CKD)
      patients. As CKD progresses, the prevalence of cardiovascular disease also increased. Beside
      traditional cardiovascular risk factor that the investigators have known, some
      non-traditional cardiovascular risk factors were reported to be associated with
      cardiovascular disease in CKD patients, which one of them was increased level of fibroblast
      growth factor-23 (FGF23).[1,2]

      FGF23 reduces production of 1,25-vitamin D3 and expression of sodium-phosphate cotransport,
      and also excretes phosphate through urine. In healthy and CKD population, increased phosphate
      level resulted in increased production of FGF23. Normophosphatemia state in early to moderate
      stage of CKD was reported due to body compensation by increasing the level of FGF23. On the
      other hand, increased serum FGF23 level was related to CKD progression, cardiomegaly,
      vascular calcification, and mortality.[1] There are several ways to prevent
      hyperphosphatemia, such as low phosphor intake, phosphate binder administration, and adequate
      dialysis.[3]

      Phosphate binder was reported to give positive effects in CKD patients with
      hyperphosphatemia. Studies which investigated the use of phosphate binder in CKD patients
      with normophosphatemia to decrease FGF23 were still limited and the result was
      controversial.[1]

      Therefore, this double blind, randomized controlled trial study investigated the
      effectiveness and safety of calcium carbonate in early to moderate CKD patients with
      normophosphatemia in lowering FGF23 levels. Study participant were randomized to receive
      calcium carbonate or placebo for 12 weeks. Before and after intervention, blood and urine
      sample were taken to examine serum FGF23, serum phosphate, urine phosphate, ionized calcium,
      serum calcium, urea, creatinine, estimated glomerular filtration rate (eGFR), and albumin.
      Effectiveness of calcium carbonate administration was indicated by serum FGF23, while safety
      was indicated by serum calcium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2015</start_date>
  <completion_date type="Actual">December 11, 2016</completion_date>
  <primary_completion_date type="Actual">December 11, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Fibroblast Growth Factor 23 (FGF-23)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum FGF23 (pg/ml) as cardiovascular risk factor in chronic kidney disease (CKD) was measured and compared between 2 groups before and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum calcium level (mg/dl) was measured and compared between 2 groups before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Calcium Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.</description>
    <arm_group_label>Calcium Carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 3 or 4 chronic kidney disease patient that visit nephrology or endocrinology
             outpatient clinic of dr. Cipto Mangunkusumo Hospital

          -  Normal level of serum phosphate

          -  Agreed to join in this study

        Exclusion Criteria:

          -  Subjects with BMI &lt; 18.5 kg/m2 or &gt; 30 kg/m2

          -  Consume drugs which may interfere bone mineral metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pringgodigdo Nugroho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maruhum Bonar H. Marbun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bella Yunita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy Astrella, MD, BMedSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>dr. Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15;305(23):2432-9. doi: 10.1001/jama.2011.826.</citation>
    <PMID>21673295</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin K, Floege J, Ketteler M. Bone and mineral metabolism in chronic kidney disease. In: Johnson R, Feehally J, Floege J, editors. Comprehensive clinical nephrology. Fifth edition. Philadelphia: Saunders; 2015. p. 984-7.</citation>
  </results_reference>
  <results_reference>
    <citation>Ketteler M, Leonard M. KDIGO 2016 Clinical practice guideline update on diagnosis, evaluation, prevention, and treatment of CKD-MBD. Off J Int Soc Nephrol. 2016;(August):1-45</citation>
  </results_reference>
  <results_reference>
    <citation>Prakash S, O'Hare AM. Interaction of aging and chronic kidney disease. Semin Nephrol. 2009 Sep;29(5):497-503. doi: 10.1016/j.semnephrol.2009.06.006.</citation>
    <PMID>19751895</PMID>
  </results_reference>
  <results_reference>
    <citation>Iseki K. Gender differences in chronic kidney disease. Kidney Int. 2008 Aug;74(4):415-7. doi: 10.1038/ki.2008.261.</citation>
    <PMID>18670407</PMID>
  </results_reference>
  <results_reference>
    <citation>Perhimpunan Nefrologi Indonesia. 8th Report of Indonesian Renal Registry. Jakarta; 2015</citation>
  </results_reference>
  <results_reference>
    <citation>Bayliss G, Weinrauch LA, D'Elia JA. Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep. 2012 Aug;12(4):440-6. doi: 10.1007/s11892-012-0288-1. Review.</citation>
    <PMID>22638939</PMID>
  </results_reference>
  <results_reference>
    <citation>Langman CB, Cannata-Andía JB. Calcium in chronic kidney disease: myths and realities. Introduction. Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S1-2. doi: 10.2215/CJN.06140809.</citation>
    <PMID>20089497</PMID>
  </results_reference>
  <results_reference>
    <citation>Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007 Sep;18(9):2600-8. Epub 2007 Jul 26.</citation>
    <PMID>17656479</PMID>
  </results_reference>
  <results_reference>
    <citation>Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, Aljama P. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol. 2013 Jul;80(1):17-22. doi: 10.5414/CN107764.</citation>
    <PMID>23391319</PMID>
  </results_reference>
  <results_reference>
    <citation>Shigematsu T, Negi S; COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant. 2012 Mar;27(3):1050-4. doi: 10.1093/ndt/gfr388. Epub 2011 Jul 19.</citation>
    <PMID>21771755</PMID>
  </results_reference>
  <results_reference>
    <citation>Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010 Feb;5(2):286-91. doi: 10.2215/CJN.05420709. Epub 2009 Nov 12.</citation>
    <PMID>19965540</PMID>
  </results_reference>
  <results_reference>
    <citation>Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.</citation>
    <PMID>22822075</PMID>
  </results_reference>
  <results_reference>
    <citation>Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85. doi: 10.2215/CJN.02830608. Epub 2008 Dec 3.</citation>
    <PMID>19056618</PMID>
  </results_reference>
  <results_reference>
    <citation>Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013 May;83(5):959-66. doi: 10.1038/ki.2012.403. Epub 2012 Dec 19.</citation>
    <PMID>23254903</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Pringgodigdo Nugroho, MD</investigator_full_name>
    <investigator_title>Head of Dialysis Unit, Dr Cipto Mangunkusumo General Hospital</investigator_title>
  </responsible_party>
  <keyword>Calcium carbonate</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Normophosphatemia</keyword>
  <keyword>FGF23</keyword>
  <keyword>Phosphate binder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

